Foley, James E <br/><br/>
Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.  [electronic resource] 

 -  Vascular health and risk management  Aug 2010 
 - 541-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1178-2048 
<br/><br/><label>Standard No.: </label>10.2147/vhrm.s10952  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adamantane--analogs & derivatives<br/>Blood Glucose--analysis<br/>Body Weight--drug effects<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Dipeptidyl-Peptidase IV Inhibitors--pharmacology<br/>Glucose--metabolism<br/>Humans<br/>Hypoglycemic Agents--adverse effects<br/>Insulin Resistance<br/>Nitriles--pharmacology<br/>Pyrrolidines--pharmacology<br/>Vildagliptin<br/>Weight Gain--drug effects